11 results on '"Etienne Daguindau"'
Number of results to display per page
Search Results
2. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide
- Author
-
Maxime Jullien, Corentin Orvain, Ana Berceanu, Marie‐Anne Couturier, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Marion Klemencie, Aline Schmidt, Mathilde Hunault, Etienne Daguindau, Xavier Roussel, Pascal Delepine, Gaelle Guillerm, Aurelien Giltat, Sylvie François, Sylvain Thepot, Steven Le Gouill, Marie‐C Béné, and Patrice Chevallier
- Subjects
allogeneic hematopoietic stem cell transplantation ,augmented comorbidity/age index ,comorbidity/age index ,haploidentical ,HSCT‐CI ,PTCY ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Three different scoring systems have been developed to assess pre‐transplant comorbidity in allogeneic hematopoietic stem cell transplantation (Allo‐HSCT): the Hematopoietic Cell Transplantation‐Specific Comorbidity Index, the Comorbidity/Age index, and the Augmented Comorbidity/Age index. All were devised to predict overall survival (OS) and disease‐free survival (DFS) survivals and non‐relapse mortality (NRM) in patients receiving HLA‐matched Allo‐HSCT, but their performance has scarcely been studied in the haploidentical Allo‐HSCT setting with post‐transplant cyclophosphamide, a procedure in constant expansion worldwide. Methods To address this issue, their impact on survivals and NRM was examined in a cohort of 223 patients treated with haploidentical Allo‐HSCT in four different centers. Results With a median follow‐up of 35.6 months, 3‐year OS, DFS, and NRM were 48.1% ± 4%, 46.3% ± 4%, and 30.0% ± 3%, respectively. No impact was found for any of the three comorbidity scores in univariate analysis. In multivariate analyses, the only three factors associated with lower OS were DRI (p
- Published
- 2021
- Full Text
- View/download PDF
3. BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
- Author
-
Margaux Poussard, Laure Philippe, Maxime Fredon, Elodie Bôle‐Richard, Sabeha Biichle, Florian Renosi, Sophie Perrin, Marie Kroemer, Samuel Limat, Francis Bonnefoy, Etienne Daguindau, Eric Deconinck, Bérengère Gruson, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, and Fanny Angelot‐Delettre
- Subjects
acute leukemia ,cell therapy ,chemotherapy ,immunology ,T cells ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy ‐ named methotrexate, idarubicine, dexamethasone, and L‐asparaginase (MIDA) ‐ and CD123 CAR‐T cell therapy. We showed that CD123 CAR‐T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients.
- Published
- 2021
- Full Text
- View/download PDF
4. Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
- Author
-
Patrice Chevallier, Myriam Labopin, Regis Peffault deLa Tour, Bruno Lioure, Claude‐Eric Bulabois, Anne Huynh, Didier Blaise, Pascal Turlure, Etienne Daguindau, Natacha Maillard, Ibrahim Yakoub‐Agha, Gaelle Guillerm, Jeremy Delage, Nathalie Contentin, Jacques‐Olivier Bay, Florence Beckerich, Jean‐Henri Bourhis, Marie Detrait, Stéphane Vigouroux, Sylvie François, Faezeh Legrand, Thierry Guillaume, Mohamad Mohty, and the SFGM‐TC
- Subjects
Acute myeloid leukemia ,allogeneic stem cell transplantation ,clofarabine ,fludarabine ,myelodysplastic syndrome ,reduced‐toxicity conditioning regimen ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract We have retrospectively compared survivals between acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received either a clofarabine/busulfan (CloB2A2) or a fludarabine/busulfan (FB2A2) RIC regimen for allogeneic stem cell transplantation. Between 2009 and 2014, 355 allotransplanted cases were identified from the SFGM‐TC registry as having received either the FB2A2 (n = 316, 56% males, median age: 59.2 years, AML 78.5%, first complete remission [CR1] 72%, median follow‐up: 20 months) or the CloB2A2 (n = 39, 62% males, median age: 60.8 years, AML 62%, CR1 69%, median follow‐up: 22.4 months) RIC regimen. In multivariate analysis, FB2A2 was associated with significant lower overall survival (OS, HR: 2.14; 95%CI: 1.05–4.35, P = 0.04) and higher relapse incidence (RI, HR: 2.17; 95%CI: 1.02–4.61, P = 0.04) and a trend for lower leukemia‐free survival (LFS, HR: 1.75; 95%CI: 0.94–3.26, P = 0.08). These results were confirmed using a propensity score‐matching strategy. However, when considering AML and MDS patients separately, the benefit of the CLOB2A2 regimen was restricted to AML patients (2‐year OS FB2A2: 38% [14.5–61.6] vs. CloB2A2: 79.2% [62.9–95.4], P = 0.01; 2‐year LFS FB2A2: 38% [16–59.9] vs. CloB2A2: 70.8% [52.6–89], P = 0.03). The better survivals were due to the lower risk of relapse in this CloB2A2 AML subgroup (2‐year RI FB2A2: 41.2% [19–62.4] vs. CloB2A2: 16.7% [5–34.2], P = 0.05). This retrospective comparison suggests that the CloB2A2 RIC regimen can likely provide longer survival than that awarded by a FB2A2 RIC regimen and may become a new standard of care RIC regimen for allotransplanted AML patients. A prospective phase 3 randomized study is warranted.
- Published
- 2016
- Full Text
- View/download PDF
5. Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with <scp>non‐Hodgkin</scp> lymphoma treated with B‐cell depleting immunotherapy
- Author
-
Roberta Di Blasi, Laure Philippe, Thomas Hueso, Catherine Thieblemont, Karine Lacombe, Bénédicte Deau Fischer, Serge Bologna, Caroline Besson, Guillemette Fouquet, Sylvain Choquet, Milena Kohn, Rémy Duléry, Carole Soussain, Bernard Drenou, Pierre Feugier, Etienne Daguindau, Marc Delord, Nicolas Noel, Adrien Chauchet, Sylvain Lamure, Sandra Malak, Cédric Rossi, Bertrand Joly, Guillaume Cartron, Yassine Taoufik, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Département d’Hématologie Clinique [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier de Versailles André Mignot (CHV), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Gustave Roussy (IGR), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Curie [Saint-Cloud], Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Oncologie de Gentilly, Centre Hospitalier Sud Francilien, CH Evry-Corbeil, Service d'Hématologie [CH Annecy], CH Annecy, Hôpital Bicêtre, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Roche, Takeda Pharmaceutical Company, TPC, We thank all the clinicians and patients in the participating centers for their contributions to this multicenter study. We are grateful to the Centre Hospitalier de Versailles, in particular Philippe Rousselot and Laure Morisset for promoting the research and for supporting the editing. We thank France Lymphome Espoir for reviewing the study material, LYSA for discussions on the design of this study, and Sophie Rigaudeau and C?cile Laur?ana for their contribution to the collection of the cases., Rémy Duléry reports personal fees from Takeda, Novartis, and Biotest and non‐financial support from Gilead outside the submitted work. Roberta Di Blasi reports personal fees from Gilead and Novartis outside the submitted work. Serge Bologna reports personal fees from Janssen and Roche outside the submitted work. Guillaume Cartron reports personal fees from Roche, Celgene, Sanofi, Gilead, Janssen, and Abbvie outside the submitted work. Karine Lacombe reports personal fees and non‐financial support from Gilead, MSD, Abbvie, ViiV Healthcare, and Janssen outside the submitted work. Caroline Besson reports research funding from Roche and non‐financial support from Takeda and Roche outside the submitted work., HAL UVSQ, Équipe, Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Groupe hospitalier de la région de Mulhouse et Sud-Alsace, Département d'Oncologie Médicale [Centre René-Huguenin, Saint-Cloud], Hôpital René HUGUENIN (Saint-Cloud), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,Male ,[SDV]Life Sciences [q-bio] ,MESH: COVID-19 / complications ,Comorbidity ,MESH: Lymphoma, Non-Hodgkin / complications ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Risk Factors ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,MESH: Age Factors ,Young adult ,Research Articles ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Aged, 80 and over ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,B-Lymphocytes ,education.field_of_study ,Lymphoma, Non-Hodgkin ,MESH: SARS-CoV-2 ,Hazard ratio ,Age Factors ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,Middle Aged ,Combined Modality Therapy ,MESH: Antigens, CD20 / immunology ,3. Good health ,030220 oncology & carcinogenesis ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Female ,Rituximab ,B-cell depleting immunotherapy ,Immunotherapy ,[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy ,Research Article ,medicine.drug ,Adult ,medicine.medical_specialty ,Population ,lymphoma ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,anti-CD20 therapy ,Young Adult ,MESH: Rituximab / administration & dosage ,03 medical and health sciences ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,MESH: COVID-19 / mortality ,Internal medicine ,medicine ,Humans ,education ,MESH: B-Lymphocytes / drug effects ,Survival analysis ,Aged ,Proportional Hazards Models ,Retrospective Studies ,MESH: Aged, 80 and over ,SARS-CoV-2 ,Proportional hazards model ,business.industry ,COVID-19 ,Retrospective cohort study ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,MESH: Combined Modality Therapy ,Length of Stay ,vaccination ,Antigens, CD20 ,medicine.disease ,Survival Analysis ,Lymphoma ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Drug Resistance, Neoplasm ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,030215 immunology - Abstract
International audience; Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants and outcomes. Adult patients with lymphoma admitted for Covid-19 to 16 French hospitals in March and April, 2020 were included. Length of in-hospital stay was analyzed as a competitor vs death. The study included 111 patients. The median age was 65 years (range, 19–92). Ninety-four patients (85%) had B-cell non-Hodgkin lymphoma. Within the 12 months prior to hospitalization for Covid-19, 79 patients (71%) were treated for their lymphoma. Among them, 63 (57%) received an anti-CD20 therapy. Fourteen patients (12%) had relapsed/refractory disease. The median LOS was 14 days (range, 1–235). After a median follow-up of 191 days (3–260), the 6-month overall survival was 69%. In multivariable analyses, recent administration of anti-CD20 therapy was associated with prolonged LOS (subdistribution hazard ratio 2.26, 95% confidence interval 1.42–3.6, p < 0.001) and higher risk of death (hazard ratio 2.17, 95% confidence interval 1.04–4.52, p = 0.039). An age ≥ 70 years and relapsed/refractory lymphoma were also associated with prolonged LOS and decreased overall survival. In conclusion, an age ≥ 70 years, a relapsed/refractory lymphoma and recent administration of anti-CD20 therapy are risk factors for prolonged LOS and death for lymphoma patients hospitalized for Covid-19. These findings may contribute to guide the management of lymphoma during the pandemic, support evaluating specific therapeutic approaches, and raise questions on the efficacy and timing of vaccination of this particular population.
- Published
- 2021
6. International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Summary
- Author
-
Pilar Solves, Miquel Lozano, Eugene Zhiburt, Javier Anguita Velasco, Ana Maria Pérez‐Corral, Silvia Monsalvo‐Saornil, Sho Yamazaki, Hitoshi Okazaki, Kathleen Selleng, Konstanze Aurich, William Krüger, Andreas Buser, Andreas Holbro, Laura Infanti, Gregor Stehle, Luca Pierelli, Antonella Matteocci, Luigi Rigacci, Karen M. K. De Vooght, Jurgen H. E. Kuball, Katherine L. Fielding, David A. Westerman, Erica M. Wood, Claudia S. Cohn, Andrew Johnson, Mickey B. C. Koh, Dara Qadir, Christine Cserti‐Gazdewich, Etienne Daguindau, Fanny Angelot‐Delettre, Pierre Tiberghien, Silvano Wendel‐Neto, Roberta‐Maria Fachini, Suzy Morton, Charles Craddock, Matthew Lumley, Jolanta Antoniewicz‐Papis, Kazimierz Hałaburda, Magdalena Łętowska, and Nancy Dunbar
- Subjects
Hematology ,General Medicine - Published
- 2021
7. BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
- Author
-
Fanny Angelot-Delettre, Eric Deconinck, Philippe Saas, Maxime Fredon, Francis Bonnefoy, Elodie Bole-Richard, Etienne Daguindau, Olivier Adotevi, Laure Philippe, Sabeha Biichle, Marie Kroemer, Margaux Poussard, Sophie Perrin, Florian Renosi, Samuel Limat, Francine Garnache-Ottou, and Berengere Gruson
- Subjects
Cell therapy ,Chemotherapy ,Acute leukemia ,business.industry ,medicine.medical_treatment ,medicine ,Cancer research ,Interleukin-3 receptor ,Car t cells ,business ,Cytotoxicity - Published
- 2020
8. International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses
- Author
-
Laura Infanti, Antonella Matteocci, Fanny Angelot-Delettre, Karen M.K. de Vooght, Kazimierz Hałaburda, Silvia Monsalvo-Saornil, Jolanta Antoniewicz-Papis, Gregor Stehle, Charles Craddock, Etienne Daguindau, Andrew D. Johnson, Erica M. Wood, Dara Qadir, Pilar Solves, Jürgen Kuball, Nancy M. Dunbar, William Krüger, Suzy Morton, Andreas Buser, Javier Anguita Velasco, Christine Cserti-Gazdewich, Miquel Lozano, Hitoshi Okazaki, Claudia S. Cohn, David Westerman, Ana Maria Pérez-Corral, Magdalena Łętowska, Roberta Fachini, Katherine L. Fielding, Matthew Lumley, Luca Pierelli, Andreas Holbro, M. Koh, E. Zhiburt, Luigi Rigacci, Kathleen Selleng, Pierre Tiberghien, Sho Yamazaki, Silvano Wendel-Neto, and Konstanze Aurich
- Subjects
Oncology ,medicine.medical_specialty ,Hematology ,business.industry ,blood group A antibody ,blood group B antibody ,thrombocyte concentrate, allogeneic hematopoietic stem cell transplantation ,allogeneic stem cell transplantation ,allotransplantation ,General Medicine ,GUIDELINES ,Transplantation ,Haematopoiesis ,Internal medicine ,medicine ,Stem cell ,business - Published
- 2021
9. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with<scp>l</scp>-asparaginase: The GRAALL experience
- Author
-
Françoise Huguet, Patrice Chevallier, Pierre Bories, Oumedaly Reman, Mathilde Hunault-Berger, Norbert Ifrah, Xavier Thomas, Véronique Lhéritier, Aline Tanguy-Schmidt, Jamile Frayfer, Corentin Orvain, Victoria Cacheux, Etienne Daguindau, Caroline Bonmati, Felipe Suarez, Véronique Dorvaux, Laurence Sanhes, Marie-Anne Couturier, Hervé Dombret, Martine Escoffre-Barbe, and Jean-Michel Pignon
- Subjects
medicine.medical_specialty ,business.industry ,Lymphoblastic lymphoma ,Central nervous system ,Antithrombin ,Induction chemotherapy ,Hematology ,medicine.disease ,Thrombosis ,Gastroenterology ,3. Good health ,Surgery ,Venous thrombosis ,medicine.anatomical_structure ,Internal medicine ,medicine ,Adult Acute Lymphoblastic Leukemia ,business ,Complication ,medicine.drug - Abstract
Central nervous system (CNS) thrombotic events are a well-known complication of acute lymphoblastic leukemia (ALL) induction therapy, especially with treatments including l-asparaginase (l-ASP). Data on risk factors and clinical evolution is still lacking in adult patients. We report on the clinical evolution of 22 CNS venous thrombosis cases occurring in 708 adults treated for ALL or lymphoblastic lymphoma (LL) with the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-induction protocol, which included eight L-ASP (6,000 IU/m2) infusions. The prevalence of CNS thrombosis was 3.1%. CNS thrombosis occurred after a median of 18 days (range: 11–31) when patients had received a median of three l-ASP injections (range: 2–7). Patients with CNS thrombosis exhibited a median antithrombin (AT) nadir of 47.5% (range: 36–67%) at Day 17 (range: D3–D28), and 95% of them exhibited AT levels lower than 60%. There were no evident increase in hereditary thrombotic risk factors prevalence, and thrombosis occurred despite heparin prophylaxis which was performed in 90% of patients. Acquired AT deficiency was frequently detected in patients with l-ASP-based therapy, and patients with CNS thrombosis received AT prophylaxis (45%) less frequently than patients without CNS thrombosis (83%), P = 0.0002). CNS thrombosis was lethal in 5% of patients, while 20% had persistent sequelae. One patient received all planned l-ASP infusions without recurrence of CNS thrombotic whereas l-ASP injections were discontinued in 20 patients during the management of thrombosis without a significant impact on overall survival (P = 0.4). Am. J. Hematol. 90:986–991, 2015. © 2015 Wiley Periodicals, Inc
- Published
- 2015
10. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes
- Author
-
Laurent Beziaud, Carole J. Henry Dunand, Christophe Ferrand, Olivier Adotevi, Adrien Chauchet, Yann Godet, Clémentine Gamonet, Jeanne Galaine, Etienne Daguindau, Charline Vauchy, Christophe Borg, Marina Deschamps, and Pierre-Simon Rohrlich
- Subjects
0303 health sciences ,Cancer Research ,Antigen presentation ,Naive B cell ,B-cell receptor ,Biology ,Molecular biology ,Epitope ,3. Good health ,B-1 cell ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,Polyclonal B cell response ,immune system diseases ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Antigen-presenting cell ,B cell ,030304 developmental biology - Abstract
Cancer-specific splice variants gain significant interest as they generate neo-antigens that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cells and in B cell lymphomas, is subject to an alternative splicing named D393-CD20 leading to loss of membrane expression of the spliced isoform. D393-CD20 expression is detectable in transformed B cells and upregulated in various lymphoma B cells. In this study, we show that D393-CD20 is translated in malignant B cells and that D393-CD20 specific CD4 T cells producing IFN-γ are present in B-cell lymphoma patients. Then, we have investigated whether the 20mer D393-CD20 peptide spanning the splicing site might be targeted by the immune system and we have shown that D393-CD20-specific CD4 Th1 clones could directly recognize malignant B cell lines and kill autologous lymphoma B cells indicating that D393-CD20-derived epitopes are naturally processed and presented on tumor cells. Finally, D393-CD20 peptide-based vaccination induced specific CD8 and CD4 T cell responses in HLA-humanized transgenic mice suggesting the presentation of D393-CD20 derived peptides on both HLA Class-I and -II. These findings support further investigations on the potential use of D393-CD20 directed specific immunotherapy in B cell malignancies.
- Published
- 2014
11. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3-4) FLUDARABINE/BUSULFAN-BASED CONDITIONING REGIMENS FOR NON-HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS
- Author
-
N. Maillard, Tony Marchand, Pascal Turlure, Etienne Daguindau, A. Le Bourgeois, J.-O. Bay, R. Peffault de Latour, S. Chantepie, P Rohrlich, Aude Charbonnier, Felipe Suarez, M. Labopin, Patrice Ceballos, Didier Blaise, Claude-Eric Bulabois, Jérôme Cornillon, E. Deconinck, I. Yakoub-Agha, S. Vigouroux, P. Chevalllier, M. Mohty, Stéphanie Nguyen, Sylvie François, and Nathalie Contentin
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Reduced intensity ,Hematology ,General Medicine ,Fludarabine ,Reduced toxicity ,Internal medicine ,medicine ,Conditioning ,Hodgkin lymphoma ,business ,Busulfan ,medicine.drug - Published
- 2017
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.